Pleased to see recent work by my group led by twitterless Dr. Emily Karange highlighted by @RecoveryAnswers in their Research Bulletin. https://t.co/XcnPyWsUB9
Very excited that @YSASVic and @WeAreTheLoopAU with several other partners have announced the location of the first fixed drug checking service in Victoria. Drug checking is a critical part of a comprehensive health-led response to substance use.
https://t.co/meO3G2Hdga
Very excited to have the opportunity via an MRFF led by @alex_guerin13 to work in this new area, with a view to preventing some of the harms of conduct disorder - including development of substance use disorder. So impressed by Alex having achieved this milestone so early!
A newly funded clinical trial, led by Orygen researcher Dr Alex Guérin, will lay the groundwork for future treatments for conduct disorder – a condition characterised by antisocial behaviours that affects over 2% of Australian children.
Details: https://t.co/PRgTm9Z6Y2
https://t.co/RGjGFVmPmG
This video explains some of the work we are doing at Orygen to work out how best to help young people with substance use problems. So grateful for my team, and that I get to do such meaningful and important work.
@DavidBarker_PhD I am not a fan of anything happening in/to NIH currently. I do think the idea of an rct of funding is great and would provide really important information to funding bodies internationally
🚨New Paper - How does the brain value cannabis vs. snacks? 🍃🍔 Using fMRI & real purchases, we found strong cannabis value signals in reward regions (vmPFC, ventral striatum, dpCC), but not for snacks. Thanks to PI & lead author @GillBedi
🔗 Read more: https://t.co/iArUatXegg
New paper from my group. Processing of subjective value for cannabis versus non drug reinforcer choices in people with frequent cannabis use https://t.co/LQT39hRaqV
An update on the Ebola outbreak in Uganda, and what the abdication of U.S. leadership in global health means for the outbreak and for us.
The first case died on Jan 29. This was a young nurse who visited multiple districts and healthcare providers, traveling by boda boda (effectively a packed sardine can on wheels). He had been sick for 10 days before dying.
His wife has now tested positive as well. There are a few other sick contacts, as well as over 140+ contacts.
The last Ebola outbreak in Uganda was in 2022. By the time investigational vaccines were mobilized, the outbreak was effectively over.
But something brilliant happened—with CDC and WHO support, Uganda set up research protocols and prepositioned vaccines for the NEXT outbreak.
SO that now, just DAYS after this outbreak was declared, a vaccine trial has already started! Healthcare workers and contacts are included in a ring vaccination trial with @IAVI's rVSV vaccine, which recently completed a Phase 1 trial in the U.S.
The fact that this vaccine trial started SO quickly after the outbreak was first reported is incredible. It's also a testament to the work that U.S.-supported organizations—including USAID and CDC—have done since the last outbreak, in partnership with WHO and Uganda, to make sure this could happen so quickly. It speaks to the value of these relationships, and what we risk losing when they fall apart or disappear.
Right now, the WHO is stepping in to fill roles normally supported by the U.S., including transport, logistics, and border screening at the airport.
We should be grateful that WHO is willing to extend its financial and human resources here, but also understand that with less U.S. support and funding, it may not be able to always do so in the future.
The point is this—the Ugandan Ministry of Health and WHO have responded quickly to this outbreak, which is amazing. Much of this quick response was built on previous U.S. support.
And without an active U.S. role in this or future outbreaks, it will be harder to contain these outbreaks at their source, fueling the possibility for greater local and international spread.
This puts everyone at greater risk.
And eventually, we here in the U.S. will come to regret pulling back on our commitments to outbreak preparedness and response around the world. That I can absolutely guarantee.
Work with us! This is a critical role with lots of independence as the lead Research Assistant for a study of Guanfacine XR for youth with Cannabis Use Disorder. Working with a complex group through YSAS , based at Orygen. Please retweet! https://t.co/vX6TlKO8vu
Work with us! This is a critical role with lots of independence as the lead Research Assistant for a study of Guanfacine XR for youth with Cannabis Use Disorder. Working with a complex group through YSAS , based at Orygen. Please retweet! https://t.co/vX6TlKO8vu
Only a few more days to apply for the @AJDAAJournal Diversity Editorial Fellowship Program 🗓️
This is a great [paid] opportunity for early career researchers who want to work closely with AJDAA Editors to learn more about the editorial process
Apply now and/or share widely!⤵️
Great [paid] opportunity for ECRs from underrepresented backgrounds to gain hands-on experience in the editorial process ⬇️
Feel free to reach out/DM with questions!
The American Journal of Drug and Alcohol Abuse has released a special collection of articles on COVID-19's impact on substance use. Dive into the latest research to understand how the pandemic has shaped addiction and recovery.
https://t.co/wCPuk7Fgye
Registrations are now open for our 2024 Symposium -
Innovations: Improving health outcomes for people who use methamphetamine and emerging drugs.
Register here: https://t.co/dpj6VCfVea